Table 5.
Multivariate Cox regression analysis for primary and composite endpoints
| Models | Renal progression |
All-cause mortality |
Composite endpoints |
||||||
|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95% CI | P | |
| Serum p-cresyl sulphate—continuous variable | |||||||||
| Unadjusted | 1.092 | 1.060–1.126 | < 0.001 | 1.099 | 1.053–1.148 | < 0.001 | 1.09 | 1.062–1.118 | < 0.001 |
| Model 1 | 1.086 | 1.52–1.121 | < 0.001 | 1.134 | 1.076–1.196 | < 0.001 | 1.089 | 1.059–1.119 | < 0.001 |
| Model 2 | 1.076 | 1.042–1.110 | < 0.001 | 1.083 | 1.033–1.136 | 0.001 | 1.075 | 1.047–1.104 | < 0.001 |
| Model 3 | 1.061 | 1.020–1.103 | 0.003 | 1.101 | 1.044–1.162 | < 0.001 | 1.074 | 1.040–1.109 | < 0.001 |
| Model 4a | 1.066 | 1.016–1.119 | 0.009 | 1.162 | 1.099–1.229 | < 0.001 | 1.094 | 1.053–1.137 | < 0.001 |
| Model 5 | 1.057 | 1.019–1.098 | 0.003 | 1.119 | 1.058–1.184 | < 0.001 | 1.075 | 1.040–1.111 | < 0.001 |
| Model 6 | 1.042 | 1.003–1.083 | 0.037 | – | – | – | 1.061 | 1.027–1.095 | < 0.001 |
| Model 7 | – | – | – | 1.136 | 1.069–1.207 | < 0.001 | 1.083 | 0.952–1.066 | < 0.001 |
| Serum indoxyl sulphate—continuous variable | |||||||||
| Unadjusted | 1.063 | 1.041–1.085 | < 0.001 | 1.014 | 0.956–1.075 | 0.647 | 1.05 | 1.028–1.071 | < 0.001 |
| Model 1 | 1.058 | 1.035–1.081 | < 0.001 | 1.022 | 0.954–1.094 | 0.536 | 1.048 | 1.025–1.071 | < 0.001 |
| Model 2 | 1.06 | 1.037–1.085 | < 0.001 | 0.997 | 0.929–1.070 | 0.932 | 1.045 | 1.022–1.069 | < 0.001 |
| Model 3 | 1.04 | 1.012–1.068 | 0.004 | 0.981 | 0.904–1.065 | 0.651 | 1.03 | 1.004–1.057 | 0.026 |
| Model 4b | 1.025 | 0.988–1.062 | 0.188 | 0.903 | 0.812–1.004 | 0.059 | 0.995 | 0.964–1.028 | 0.769 |
| Model 5 | 1.034 | 1.004–1.064 | 0.028 | 0.97 | 0.876–1.074 | 0.558 | 1.025 | 0.995–1.056 | 0.104 |
| Model 6 | 1.033 | 1.004–1.064 | 0.027 | – | – | – | 1.023 | 0.994–1.053 | 0.119 |
| Model 7 | – | – | – | 0.984 | 0.895–1.083 | 0.748 | 1.007 | 0.983–1.032 | 0.576 |
Model 1 was adjusted for age (1-year increment), male gender and diabetes status.
Model 2 was adjusted for serum albumin (1 g/L increments).
Model 3 was adjusted for eGFR (1 mL/min increments).
Model 4a was adjusted for indoxyl sulphate (1 mg/L increments).
Model 4b was adjusted for p-cresyl sulphate (1 mg/L increments).
Model 5 was adjusted for Ca × P product (1 mg2/dL2 increments), intact parathyroid hormone (log 1 pmol/L increments), haemoglobin (1 g/dL increments) and hs-CRP (log 1 mg/L increments).
Model 6 was adjusted by hierarchically selected covariates of albumin, Ca × P product, eGFR, diabetes status and gender.
Model 7 was adjusted for hierarchically selected covariates of age, hs-CRP, albumin and haemoglobin.